GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.

Potluri, Hemanth K et al.·Cancer immunology·2022·
RPEP-064352022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Antibody responses to 5680 peptides were detected only with GM-CSF as an adjuvant.

Key Numbers

How They Did This

The study evaluated sera from prostate cancer patients in four clinical trials, using a peptide array of 177,604 peptides.

Why This Research Matters

Understanding how GM-CSF influences antibody production can improve vaccine strategies for prostate cancer. This research suggests that antibody responses may not reliably indicate immune spread, prompting a reevaluation of assessment methods.

What This Study Doesn't Tell Us

The study focuses on antibody responses and does not assess T cell responses directly, which may provide a more accurate measure of immune spread.

Trust & Context

Original Title:
GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.
Published In:
Cancer immunology, immunotherapy : CII, 71(9), 2267-2275 (2022)
Database ID:
RPEP-06435

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06435·https://rethinkpeptides.com/research/RPEP-06435

APA

Potluri, Hemanth K; Ng, Tun L; Newton, Michael A; McNeel, Douglas G. (2022). GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.. Cancer immunology, immunotherapy : CII, 71(9), 2267-2275. https://doi.org/10.1007/s00262-022-03150-3

MLA

Potluri, Hemanth K, et al. "GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.." Cancer immunology, 2022. https://doi.org/10.1007/s00262-022-03150-3

RethinkPeptides

RethinkPeptides Research Database. "GM-CSF elicits antibodies to tumor-associated proteins when ..." RPEP-06435. Retrieved from https://rethinkpeptides.com/research/potluri-2022-gmcsf-elicits-antibodies-to

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.